Sarpeta Slammed On Possible Reason For Delay In FDA Final Decision On Eteplirsen

Sarepta Therapeutics

shares are trading lower by $4 at $17.41. Concerns over the upcoming decision on Eteplirsen has investors exiting the issue in a big way. The selling from the premarket session has spilled over into the regular session. After a lower open, it only manged $0.08 bounce to $19.98 before more sellers piled into the issue. So far, the ensuing decline has the taken the issue to $17.05 and it is attempting to rebound. That low coincides with a series of four lows in the issue from $16.84 to $17.22 in mid-May.